The food and drugs of the United States (FDA) approved on March 28 the use of ocrelizumab (Ocrevus) – developed by Roche – to treat recurrent (EMR) to patients with multiple sclerosis and multiple sclerosis primary progressive (PPMs), which are the two forms of the disease who suffer most affected when they are diagnosed.
The PPMs affects about 15% of the patients who are diagnosed with multiple sclerosis
As explained by Sandra Horning, Chief Medical Officer and head of Global product development of Roche, it is a significant step forward for patients, ocrelizumab, which every six months is given intravenously, is the first multiple sclerosis treatment approved by the FDA that can modify the course of recurrent forms and PPMs , a very disabling of this pathology manifestation.
Effective to prevent relapses and reduce disability
And it is that the studies phase III carried out to verify the effectiveness of this drug, during the period of controlled treatment of two years found that 46-47% reduced the relapse rate by year, delayed the worsening of disability and decreased significantly in the brain lesions observed through magnetic resonance imaging, to compare with high doses of interferon beta-1a.
Primary progressive multiple sclerosis, for which up to now were not available therapies approved by the FDA, affects about 15% of the patients who are diagnosed with multiple sclerosis, and is characterized by a continuous worsening of the symptoms and the subsequent progression of disability, of there the importance that has for these people have this new therapeutic option.